Peer2Peer | Why OMIDRIA Matters: Enhancing Outcomes and Reducing Burden скачать в хорошем качестве

Peer2Peer | Why OMIDRIA Matters: Enhancing Outcomes and Reducing Burden

Dr Paul Singh and Dr Kendall Donaldson come together at the AECOS 2025 to explore the evolving role of OMIDRIA in cataract surgery. As the only FDA-approved intracameral NSAID, OMIDRIA continues to deliver meaningful clinical benefit - reducing inflammation, preventing complications, and improving patient outcomes - while easing or removing the burden of post-op drop regimens. The conversation dives into compelling new evidence: NSAIDs alone have been shown to result in a two-times lower rate of CME at 6 weeks compared to steroid monotherapy, and combining an NSAID with a steroid offers the best inflammation control versus either drug alone. The hosts also discuss findings showing no statistically significant differences between dropless and topical regimens in inflammation at any time point, complication rates (including IOP spikes), macular thickness changes, CME incidence, or patient-reported pain/discomfort - reinforcing the value of OMIDRIA in flexible, patient-friendly post-op care models. Listeners will hear real-world insights from the Bascom study and clinical practice, including how OMIDRIA-based dropless protocols can streamline workflow, enhance staff efficiency, improve patient satisfaction, and reduce costs. Importantly, OMIDRIA now maintains separate payment status in both Ambulatory Surgery Centers (ASCs) and Hospital Outpatient Departments (HOPDs) for 100% of fee-for-service Medicare patients.* *OMIDRIA qualifies for separate payment across both ASC and HOPD settings as it fulfils the requirements established in the non-opioid as a surgical supply provision by CMS. For more, browse the OMIDRIA content at omidria.com Rayner, the Rayner logo, OMIDRIA, and the OMIDRIA logo, are proprietary marks of Rayner. © 2025 Rayner Group, all rights reserved. OMIDRIA videos and podcasts are for the attention of US HCPs only. Please rely on your clinical judgment when considering treatment approaches. A dropless approach with OMIDRIA may not suit all patients. Rayner does not recommend specific product combinations. As of August 2025, OMIDRIA is approved in the US and UK. Speakers may be paid Rayner consultants. US-OM-2500051 07/25